Bobak Azamian compensation by year
Tarsus Pharmaceuticals Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $300,000 | $437,000 | $550,000 | $590,000 | $619,500 | $673,400 | $726,333 |
| Bonus | $116,137 | $211,484 | $269,500 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $876,822 | $1,029,364 | $3,370,153 | $2,648,284 |
| Option awards | $0 | $1,847,092 | $6,029,589 | $2,077,378 | $1,017,968 | $3,267,692 | $2,651,487 |
| Non-equity incentive | $0 | $0 | $0 | $324,500 | $450,300 | $532,800 | $555,700 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $14,820 | $21,634 | $47,580 | $13,200 | $52,147 | $36,175 |
| Total | $416,137 | $2,510,396 | $6,870,723 | $3,916,280 | $3,130,332 | $7,896,192 | $6,617,979 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 28, 2026, accession 0001819790-26-000028, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Tarsus Pharmaceuticals, Inc. filed document, accession 0001819790-26-000028. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 69,364 | $5,679,524 | — |
| RSU | 59,512 | $4,872,843 | — |
| RSU | 33,950 | $2,779,826 | — |
| PSU | 22,318 | $1,827,398 | — |
| RSU | 11,300 | $925,244 | — |
| Option | 9,630 | — | $19.59 |
| Option | 31,327 | — | $15.00 |
| Option | 77,034 | — | $35.50 |
| Option | 90,736 | — | $44.54 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Tarsus Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-04 | Sale | 10b5-1 | 7,100 | $90.27 | 830,891 |
| 2026-09-04 | Sale | 10b5-1 | 2,900 | $91.27 | 827,991 |
| 2026-09-02 | Sale | 10b5-1 | 10,000 | $80.06 | 837,991 |
| 2026-06-17 | Sale | 10b5-1 | 5,418 | $61.81 | 847,991 |
| 2026-06-17 | Sale | 10b5-1 | 4,582 | $61.24 | 853,409 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Tarsus Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bobak Azamian · this page | President, Chief Executive Officer and Board Chairman | $6,617,979 |
| Aziz Mottiwala | Chief Commercial Officer | $2,789,529 |
| Jeffrey Farrow | Chief Financial Officer and Chief Strategy Officer | $2,677,617 |
| Seshadri Neervannan | Chief Operating Officer | $2,628,172 |
| Bryan Wahl | General Counsel and Corporate Secretary | $2,560,205 |
Board service
Tarsus Pharmaceuticals board · FY2023–FY2025How this board is paid
Company policy: Tarsus Pharmaceuticals pays directors a $50,000 cash retainer and $270,000 in equity. As stated in Tarsus Pharmaceuticals's FY2025 proxy.
The full Tarsus Pharmaceuticals compensation record
free company briefThis page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Tarsus Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Tarsus Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TARS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.